The company's principal activity is to develop and market pharmaceutical products for the treatment of cancer and atherosclerosis. The products of the company include xcytrin(R) and antrin (r). These products represent a new class of drugs called texaphyrins, rationally designed, porphyrin-like molecules, that are capable of upsetting the intracellular oxidation-reduction balance and disrupting the bioenergetic processes in diseased tissue. The company is conducting a multicenter international phase iii clinical trial of xcytrin(R) (motexafin gadolinium) injection, to improve the efficacy of radiation therapy of tumors that have spread to the brain resulting from a variety of cancers, including those of the lung and breast. The company is in the development stage.
